Pan Zhao1, Jun-Bin Liang2, Zhong-Yang Deng1, Ming-Jing Wang1, Jia-Yue Qin2, Chong-Jian Chen3, Xiao-Mei Hu4. 1. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. 2. Annoroad Gene Technology Co. Ltd., Beijing, 100176, China. 3. Annoroad Gene Technology Co. Ltd., Beijing, 100176, China. cchen@annoroad.com. 4. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. huxiaomei_2@163.com.
Abstract
OBJECTIVES: To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (, CQHP) in patients with myelodysplastic syndrome (MDS). METHODS: Forty-three MDS patients were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed. RESULTS: Up to 41.86% of patients harbored genet mutations, in most cases with more than one mutation. The most common mutations were in SF3B1, U2AF1, ASXL1, and DNMT3A. After treatment with CQHP, about 88.00% of patients no longer required blood transfusion, or needed half of prior transfusions. CONCLUSIONS: CQHP is an effective treatment for patients with MDS, especially those with gene mutations in SF3B1, DNMT3A, U2AF1, and/or ASXL1.
OBJECTIVES: To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (, CQHP) in patients with myelodysplastic syndrome (MDS). METHODS: Forty-three MDSpatients were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed. RESULTS: Up to 41.86% of patients harbored genet mutations, in most cases with more than one mutation. The most common mutations were in SF3B1, U2AF1, ASXL1, and DNMT3A. After treatment with CQHP, about 88.00% of patients no longer required blood transfusion, or needed half of prior transfusions. CONCLUSIONS:CQHP is an effective treatment for patients with MDS, especially those with gene mutations in SF3B1, DNMT3A, U2AF1, and/or ASXL1.
Authors: Peter Valent; Hans-Peter Horny; John M Bennett; Christa Fonatsch; Ulrich Germing; Peter Greenberg; Torsten Haferlach; Detlef Haase; Hans-Jochen Kolb; Otto Krieger; Michael Loken; Arjan van de Loosdrecht; Kiyoyuki Ogata; Alberto Orfao; Michael Pfeilstöcker; Björn Rüter; Wolfgang R Sperr; Reinhard Stauder; Denise A Wells Journal: Leuk Res Date: 2007-01-25 Impact factor: 3.156
Authors: Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian Journal: Blood Date: 2006-05-04 Impact factor: 22.113
Authors: Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell Journal: Blood Date: 2013-09-12 Impact factor: 22.113
Authors: Sun Shuzhen; Ma Rou; Hu Xiaomei; Yang Xiao-Hong; Xu Yong-Gang; Wang Hongzhi; Yang Xiu-Peng Journal: Evid Based Complement Alternat Med Date: 2012-10-16 Impact factor: 2.629